AU590578B2 - Treatment of non-ulcer dyspepsia with bismuth salts - Google Patents
Treatment of non-ulcer dyspepsia with bismuth saltsInfo
- Publication number
- AU590578B2 AU590578B2 AU59026/86A AU5902686A AU590578B2 AU 590578 B2 AU590578 B2 AU 590578B2 AU 59026/86 A AU59026/86 A AU 59026/86A AU 5902686 A AU5902686 A AU 5902686A AU 590578 B2 AU590578 B2 AU 590578B2
- Authority
- AU
- Australia
- Prior art keywords
- ulcer dyspepsia
- antibiotics
- bismuth salt
- antibiotic
- amoxycillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 201000006549 dyspepsia Diseases 0.000 title claims description 22
- 150000001621 bismuth Chemical class 0.000 title claims description 15
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 10
- 229960003022 amoxicillin Drugs 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 6
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical group [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 6
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960005053 tinidazole Drugs 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 3
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000001622 bismuth compounds Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010015137 Eructation Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000007238 Postcholecystectomy Syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- -1 nitro-imidazole sulfones Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
TREATMENT OF NON-ULCER DYSPEPSIA WITH BISMUTH SALTS BACKGROUND ART This invention relates to a method of treating non-ulcer dyspepsia . In the past bismuth compounds have been used in the treatment of dyspepsia arising from peptic ulcers. However, there has been previously no recognised therapy for the treatment of non-ulcer dyspepsia. Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", "irritable bowel syndrome", "gastritis", and also "post-cholecystectomy syndrome". Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
The treatment of this disorder has, until now, been non-specific, empirical and generally inadequate.
It has now been discovered that a new class of sp.iral bacteria reside in the stomach of humans. These bacteria have been found to be closely associated with the presence of gastritis. It has now also been found that the symptoms of non-ulcer dyspepsia are closely related to the presence of the newly discovered spiral bacteria. These bacteria are Campylobacter-like bacteria, currently called Campylobacter pyloridis.
While the use of bismuth salts to treat ulcers has been known, their utility in the treatment of non-ulcer dyspepsia has not been suspected previously. The symptoms of the two conditions are generally different, but may at times overlap. The diagnosis is made endoscopically.
DISCLOSURE OF THE INVENTION The present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
A preferred bismuth compound for the treatment of
non-*αlcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
It has further been found that the treatment of non-ulcer dyspepsia with bismuth salt is enhanced by the concurrent administration of an antibiotic.
Particularly suitable antibiotics may be chosen from the classes consisting of β-lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
Another aspect of the invention comprises a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
Preferably the bismuth salt is tripotassium dicitrato-bismuthate.
The most preferable antibiotics are selected from the classes specified above. In particular, the β-lactam antibiotics. Most preferably, the antibiotic is Amoxycillin. The pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.
BEST MODE OF CARRYING OUT THE INVENTION The invention will now be further described with reference to the following examples. Example 1
27 Patients suffering from non-ulcer dyspepsia associated with C.pyloridis infection were treated with the bismuth salt, tripotassium dicitrato-bismuthate, known under the registered Trade Mark "De-Nol". All patients were administered 107.7mg De-Nol four times daily. Of the 27, 6 were treated with De-Nol alone. Of these it was found that
40% were completely clear of dyspepsia after 1 month and 60% after two months. The remaining patients were treated with combinations of De-Nol and the antibiotics Amoxycillin and Tinidazole. 250mg Amoxycillin was administered four times daily for four weeks and lgm Tinidazole was administered daily for 10 days. The results were 95% clear completely within 4 weeks. Rebiopsy of the completely clear patients, performed 2 weeks after the four week treatment ceased, showed that the patients remained completely clear.
Trials with Amoxycillin alone indicate that Amoxycillin has no appreciable effect in the treatment of dyspepsia. Example 2
The following pharmaceutical formulation is proposed for use in the performance of the present invention: Tablet formulation tripotassium dicitrato-bismuthate 107.7mg amoxycillin 250 mg magnesium.stearate 10 mg maize starch 20 mg
Flavouring substances may be added as required. It will be clear to those skilled in the art that other formulations falling within the scope of the present invention are possible, and that the invention is therefore not restricted to the above formulation.
Claims
1. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia associated with Campylobacter pyloridis infection, comprising administering to said patients an effective amount of a pharmaceutically acceptable bismuth salt.
2. A method according to claim 1 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
3. A method according to claim 1 wherein the bismuth salt is administered in conjunction with one or more antibiotics.
4. A method according to claim 3 wherein the antibiotics are selected from the β-lactam antibiotics, macrolide anitbiotics, tetracycline antibiotics and nitro-imidazole sul ones.
5. A method according to claim 4 wherein the antibiotics are selected from Amoxycillin, Tinidazole, Erythromycin and Tetracycline.
6. A method according to claim 5 wherein Amoxycillin and Tinidazole are administered in conjunction with the bismuth salt.
7. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia, substantially as hereinbefore described with reference to the examples.
8. A pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
10. A pharmaceutical composition according to either one of claims 8 or 9 wherein the antibiotic is a β-lactam antibiotic.
11. A pharmaceutical formulation according to claim 10 wherein the antibiotic is Amoxycillin.
12. A pharmaceutical formulation substantially as hereinbefore described with reference to the examples.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH019885 | 1985-04-18 | ||
| AUPH0198 | 1985-04-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5902686A AU5902686A (en) | 1986-11-05 |
| AU590578B2 true AU590578B2 (en) | 1989-11-09 |
Family
ID=3771057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU59026/86A Expired AU590578B2 (en) | 1985-04-18 | 1986-04-18 | Treatment of non-ulcer dyspepsia with bismuth salts |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0222834A4 (en) |
| JP (1) | JPS62502967A (en) |
| AU (1) | AU590578B2 (en) |
| SG (1) | SG72632A1 (en) |
| WO (1) | WO1986005981A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU621285B2 (en) * | 1987-03-09 | 1992-03-12 | Procter & Gamble Company, The | Compositions and methods for treating gastrointestinal disorders |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0206625B1 (en) * | 1985-06-13 | 1992-09-30 | Barry James Dr. Marshall | Compositions for the treatment of gastrointestinal disorders |
| DE3874917T2 (en) * | 1987-03-09 | 1993-03-04 | Procter & Gamble | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH. |
| AU623868B2 (en) * | 1987-10-12 | 1992-05-28 | Capability Services Pty. Limited | Improved method for treatment of gastrointestinal disorders |
| DE3887353T2 (en) * | 1987-10-12 | 1994-05-05 | Capability Services Pty Ltd | TREATMENT PROCEDURE FOR STOMACH-DISEASES. |
| US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
| EP0375068A1 (en) * | 1988-12-23 | 1990-06-27 | Gist-Brocades N.V. | Combining bismuth compounds and tetracyclines |
| EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
| FI910088A7 (en) * | 1990-01-09 | 1991-07-10 | Brocades Pharma Bv | Oral pharmaceutical composition |
| YU45590A (en) * | 1990-03-07 | 1992-07-20 | PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. | NEW COMPLEXES OR CHELATES OF ANTIBIOTICS WITH TWO-VALENT AND / OR TROVALENT METALS AND PROCEDURES FOR THEIR OBTAINING |
| GB9010039D0 (en) * | 1990-05-03 | 1990-06-27 | Reckitt & Colmann Prod Ltd | Medicament preparation |
| US5192752A (en) * | 1991-01-14 | 1993-03-09 | The Procter & Gamble Company | Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate |
| GB9120131D0 (en) * | 1991-09-20 | 1991-11-06 | Glaxo Group Ltd | Medicaments |
| ATE184198T1 (en) * | 1993-05-11 | 1999-09-15 | Spirig Ag | SOLID MEDICINAL PREPARATION CONTAINING BISMUTH AND AMOXYCILLINE AND ITS USE |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US5834002A (en) | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| PE48297A1 (en) * | 1995-05-09 | 1998-02-04 | Procter & Gamble | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS |
| US5702729A (en) * | 1995-12-07 | 1997-12-30 | The Procter & Gamble Company | Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria |
| US5744168A (en) * | 1995-12-07 | 1998-04-28 | The Procter & Gamble Company | Methods and compositions for the prevention and treatment of gastrointestinal disorders |
| US6051604A (en) * | 1995-12-07 | 2000-04-18 | The Proctor & Gamble Company | Methods and compositions for the prevention and treatment of gastrointestinal disorders |
| AUPS088702A0 (en) | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
| US11829518B1 (en) | 2004-07-28 | 2023-11-28 | Ingeniospec, Llc | Head-worn device with connection region |
| NZ611868A (en) | 2010-12-13 | 2015-11-27 | Salix Pharmaceuticals Inc | Gastric and colonic formulations and methods for making and using them |
| AU2013294737B2 (en) | 2012-07-27 | 2018-05-24 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2053002A1 (en) * | 1969-06-21 | 1971-04-16 | Clin Midy | Bismuth slats of alpha methiminobenzyl - penicillin |
| AU440535B2 (en) * | 1969-12-18 | 1973-09-17 | Export Drugs Company | Antacid compositions |
| AU563692B2 (en) * | 1981-09-22 | 1987-07-16 | Brocades Pharma B.V. | Bismuth containing composition and method for the preparationthereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6063965A (en) * | 1965-06-25 | 1967-01-05 | Morton W. Scott | Belayed acting compositions |
| US3621094A (en) * | 1968-04-05 | 1971-11-16 | Smith Kline French Lab | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts |
| IL32020A (en) * | 1968-04-18 | 1972-11-28 | Brown G | Antacid compositions |
| GB1220819A (en) * | 1968-04-24 | 1971-01-27 | Mar Pha Soc D Etude Et D Expl | Improved bismuth salt |
| US4153685A (en) * | 1968-11-23 | 1979-05-08 | Schering Corporation | Bismuth complex preparations |
| FR2029402A1 (en) * | 1969-01-28 | 1970-10-23 | Breive Et Son Jib Labo | Regulation of digestion in gastro intestinal - passage |
| FR2073254A2 (en) * | 1969-12-04 | 1971-10-01 | Dausse Laboratoire | Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders |
| FR2092636A1 (en) * | 1970-06-03 | 1972-01-28 | Griffon Henri | Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders |
| ZA74385B (en) * | 1974-01-18 | 1975-08-27 | Gist Brocades Nv | Pharmaceutical compositions |
| HU179474B (en) * | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
| US4588589A (en) * | 1983-10-13 | 1986-05-13 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| DE3686362T2 (en) * | 1985-06-13 | 1993-02-11 | Marshall Barry James | METHOD FOR TREATING GASTRIC DISEASES. |
| EP0206625B1 (en) * | 1985-06-13 | 1992-09-30 | Barry James Dr. Marshall | Compositions for the treatment of gastrointestinal disorders |
-
1986
- 1986-04-18 AU AU59026/86A patent/AU590578B2/en not_active Expired
- 1986-04-18 SG SG1996004300A patent/SG72632A1/en unknown
- 1986-04-18 EP EP19860903120 patent/EP0222834A4/en not_active Ceased
- 1986-04-18 WO PCT/AU1986/000106 patent/WO1986005981A1/en not_active Ceased
- 1986-04-18 JP JP61502999A patent/JPS62502967A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2053002A1 (en) * | 1969-06-21 | 1971-04-16 | Clin Midy | Bismuth slats of alpha methiminobenzyl - penicillin |
| AU440535B2 (en) * | 1969-12-18 | 1973-09-17 | Export Drugs Company | Antacid compositions |
| AU563692B2 (en) * | 1981-09-22 | 1987-07-16 | Brocades Pharma B.V. | Bismuth containing composition and method for the preparationthereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU621285B2 (en) * | 1987-03-09 | 1992-03-12 | Procter & Gamble Company, The | Compositions and methods for treating gastrointestinal disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62502967A (en) | 1987-11-26 |
| EP0222834A4 (en) | 1989-10-04 |
| SG72632A1 (en) | 2000-05-23 |
| WO1986005981A1 (en) | 1986-10-23 |
| AU5902686A (en) | 1986-11-05 |
| EP0222834A1 (en) | 1987-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU590578B2 (en) | Treatment of non-ulcer dyspepsia with bismuth salts | |
| US5256684A (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| CA1277232C (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| US5601848A (en) | Methods for the treatment of gastrointestinal disorders | |
| US5629297A (en) | Medicament for treating gastrointestinal disorders | |
| CA2344308C (en) | Taurolidine and/or taurultam against infectious ulcer or gastritis | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| Hewitt | The penicillins: a review of strategy and tactics | |
| US4959384A (en) | Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
| Labenz et al. | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease | |
| KR20010024050A (en) | Antimicrobials | |
| EP0591446B1 (en) | Method for treating helicobacter pylori gastritis | |
| Glupczynski | In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection | |
| RU2076708C1 (en) | Pharmaceutical composition and method of gastroenteric sickness treatment and prophylaxis | |
| RU2187318C2 (en) | Method of healing chronic gastritis and duodenum ulcer disease | |
| EP0865286B1 (en) | Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders | |
| JPH0920668A (en) | Antibacterial agent for helicobacter pylori as slightly aerobic gram-negative bacillus | |
| O’Morain | How to eradicate Helicobacter pylori and prevent reinfection | |
| Reinfection | How to Eradicate Helicobacter pylori |